- Home
- WMPN vs AVTX Comparison
WMPN vs AVTX Comparison
Compare WMPN & AVTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WMPN
- AVTX
- Stock Information
- Founded
- WMPN 1870
- AVTX 2011
- Country
- WMPN United States
- AVTX United States
- Employees
- WMPN N/A
- AVTX N/A
- Industry
- WMPN Savings Institutions
- AVTX Biotechnology: Pharmaceutical Preparations
- Sector
- WMPN Finance
- AVTX Health Care
- Exchange
- WMPN Nasdaq
- AVTX Nasdaq
- Market Cap
- WMPN 112.6M
- AVTX 90.9M
- IPO Year
- WMPN N/A
- AVTX 2015
- Fundamental
- Price
- WMPN $13.02
- AVTX $9.65
- Analyst Decision
- WMPN Buy
- AVTX Buy
- Analyst Count
- WMPN 1
- AVTX 2
- Target Price
- WMPN $14.00
- AVTX $35.00
- AVG Volume (30 Days)
- WMPN 89.0K
- AVTX 68.6K
- Earning Date
- WMPN 10-16-2024
- AVTX 11-07-2024
- Dividend Yield
- WMPN 0.92%
- AVTX N/A
- EPS Growth
- WMPN N/A
- AVTX N/A
- EPS
- WMPN N/A
- AVTX N/A
- Revenue
- WMPN $20,360,000.00
- AVTX $820,000.00
- Revenue This Year
- WMPN N/A
- AVTX N/A
- Revenue Next Year
- WMPN N/A
- AVTX N/A
- P/E Ratio
- WMPN N/A
- AVTX N/A
- Revenue Growth
- WMPN N/A
- AVTX N/A
- 52 Week Low
- WMPN $10.80
- AVTX $3.95
- 52 Week High
- WMPN $13.45
- AVTX $34.46
- Technical
- Relative Strength Index (RSI)
- WMPN 56.24
- AVTX 33.29
- Support Level
- WMPN $12.83
- AVTX $12.00
- Resistance Level
- WMPN $13.45
- AVTX $13.59
- Average True Range (ATR)
- WMPN 0.28
- AVTX 0.95
- MACD
- WMPN -0.02
- AVTX -0.49
- Stochastic Oscillator
- WMPN 63.57
- AVTX 1.25
About WMPN William Penn Bancorporation
William Penn Bancorporation operates as an independent community financial services provider. The bank offers traditional banking and related financial services to individual, business, and government customers. Through its branch and automated teller machine network, the bank offers a full array of commercial and retail financial services, including; the taking of time, savings, and demand deposits; the making of commercial, consumer, and mortgage loans; and the providing of other financial services.
About AVTX Avalo Therapeutics Inc.
Avalo Therapeutics Inc is a clinical stage biotechnology company focused on the treatment of immune dysregulation. The company's lead asset is AVTX-009, an anti-IL-1B monoclonal antibody ("mAb"), targeting inflammatory diseases. Avalo's pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein).